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Abstract
The role of exercise electrocardiography (ECG) and stress echocardiography (SE) in the management of patients with 
valvular heart diseases (VHD) has been reviewed in this article relying on the recent evidence and the recommendations 
of the European Society of Cardiology/European Association of Cardio-Thoracic Surgery (ESC/EACTS) and the American 
College of Cardiology/American Heart Association (ACC/AHA) guidelines on the management of VHD. Both guidelines 
emphasise the role of exercise ECG to unmask objectively the occurrence of symptoms in patients, who deny symptoms 
or have doubtful symptoms; however, the role of SE to assess the haemodynamic component of VHD and unmask subcli-
nical myocardial dysfunction is questioned. The above-mentioned guidelines strongly recommend deciding regarding 
valve surgery according to the presence of symptoms and the left ventricular (LV) morphological and functional para-
meters assessed at rest. SE can be useful in selected VHD patients for the determination of prognosis, clarification of 
symptoms and deciding on the timing of surgery. Despite existing evidence, there is still a need for randomised clinical 
outcome trials evaluating the role of stress imaging in the daily practise decision-making.
Keywords: exercise electrocardiography, stress echocardiography, dobutamine echocardiography, exercise  
echocardiography, stress imaging, valvular heart diseases
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Introduction
Most of the patients having severe VHD are asymptoma-
tic. However, not every asymptomatic patient is certainly 
without symptoms, because many valve diseases progress 
slowly, thus patients gradually limit their daily activity le-
vels and may not recognise any symptoms [1]. The main 
purpose of the exercise testing is to unmask objectively the 
occurrence of symptoms in patients, who deny symptoms 
or have doubtful symptoms, and is especially useful for risk 
stratification in aortic stenosis (AS) [2]. According to ACC/ 
/AHA guidelines, exercise testing is reasonable in patients 
with asymptomatic severe VHD in order to confirm the ab-
sence of symptoms, assess the haemodynamic response 
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to exercise and determine the prognosis (IIaB) [3]. Additio-
nally, exercise testing can be useful for determination of 
the level of authorised physical activity, including partici-
pation in sports [2]. Therefore both the above-mentioned 
guidelines strongly support the use of exercise testing in 
the assessment of VHD [2, 3]. Importantly, the predictive 
values of functional stress tests used for the diagnosis of 
coronary heart disease (CHD) may not apply in the presence 
of VHD and these tests are generally not used in the setting 
of advanced VHD [4].
SE is more sophisticated test than simple exercise 
ECG, because it evaluates clinical responses during exer-
cise, together with the assessment of the haemodynamic 
changes that can be missed at rest. The problem with 
SE is that this modality is not widely accessible, could be 
technically demanding, and requires specific expertise. 
The purpose of this review article is to update the evidence 
and recommendations regarding the role of exercise ECG 
and SE, especially exercise echocardiography (EE), in the 
management of VHD patients.
Stress protocols
Before performing stress testing in patients with VHD, 
a comprehensive clinical evaluation, including a comple-
te resting transthoracic echocardiogram, is obligated in 
order to rule out the presence of symptom and to identify 
potential contraindications. Patients with a significant left 
VHD are referred to surgery as soon as they experience 
symptoms. The contraindications to perform a SE in VHD 
are almost the same as for the evaluation of CHD: 1) clear 
to VHD related symptoms; 2) clear indications for valve 
surgery (i.e., symptomatic severe AS or mitral stenosis 
(MS); 3) high blood pressure (BP) (systolic > 200 mm Hg 
or diastolic > 110 mm Hg); 4) uncontrolled or symptoma-
tic arrhythmias; 5) systemic illness; 6) physical or mental 
diseases making the adequate performing of an exercise 
test impossible [5, 6].
While performing the stress test, stress may be induced 
physically by exercise or pharmacologically, e.g. by dobu-
tamine. Exercise testing is preferred over pharmacological 
stress for evaluation of patients with VHD, as the exercise 
capacity is a significant predictor of the outcome [7]. 
Pharmacological stress with dobutamine has limited utility 
in the setting of VHD, except in patients having the true 
low-flow, low-gradient aortic stenosis (LFLG AS). Exercise 
test can be performed by using either treadmill or supine/
semi-supine bicycle. Supine/semi-supine bicycle is a better 
technique, because of its‘ possibility to perform imaging 
during exercise, while with treadmill, imaging may be per-
formed only before and after exercise [1]. Post-exercise 
echocardiography can also be performed, but the time to 
acquire images during recovery is short and it is technically 
demanding. In our clinic, bicycle exercise ECG is performed 
in supine or semi-supine position and EE is performed using 
semi-supine bicycle. Semi-supine bicycle with tilting and 
rotating table, which is the preferred approach in Europe, 
is more physiological and permits optimal image acquisition 
during each step of exercise testing, i.e., per-exercise echo-
cardiography. This modality is strongly suggested by the 
experts of VHD to detect quickly disappearing changes [8]. 
Treadmill exercise testing using modified Bruce protocol is 
more commonly used in North America, and is mentioned in 
ACC/AHA guidelines as the preferred exercise modality [3].
While performing EE for VHD patient, a symptom-limited 
graded approach is recommended, trying to reach at least 
85% of the age-predicted heart rate in the absence of 
symptoms. Patients should continue taking their usual 
medication(s), because abnormal exercise testing results 
while patients are taking suboptimal therapy might be 
confusing for clinical decision-making. The test should be 
performed under the supervision of an experienced and tra-
ined operator (sonographer or cardiologist) with continuous 
monitoring of BP, 12-lead ECG, heart rate (HR) and appe-
arance of symptoms (hypotension, ventricular arrhythmia 
and etc.). Additional echocardiographic valve parameters, 
the LV and the haemodynamic consequences of valve 
disease (e.g. pulmonary arterial pressure) are recorded at 
rest, at each increment of workload (if not possible, only 
at peak exercise) and during recovery. The workload sho-
uld be adjusted for each patient, i.e. we begin a test with 
a workload of 50 W and increase it by 25 W every 3 minutes 
in a younger patient with AS, whereas an initial workload 
of 25 W with an increase of workload by 10 or 25 W (de-
pending on patients’ functional status) every 2 minutes is 
more suitable and comfortable for an older patient with LV 
dysfunction and ischaemic mitral regurgitation (MR) [5, 6]. 
Exercise testing should be interrupted, when the target 
HR is reached or if the patient presents with the typical 
chest pain, dizziness, hypotension (decrease in systolic 
BP ≥ 20 mm Hg), limiting dyspnoea, significant complex 
ventricular arrhythmia, or muscular exhaustion. The test 
is considered positive if the patient encounters ≥ 1 of the 
following criteria: typical angina, limiting dyspnoea, ≥ 2 mm 
horizontal or down-sloping ST segment depression, synco-
pe or near syncope, decrease or < 20 mm Hg increase in 
systolic BP, or complex ventricular arrhythmias [6].
Dobutamine stress echocardiography (DSE) is useful 
approach is the setting of a true LFLG AS. We use a low-
-dose dobutamine protocol starting with 5 μg/kg per minute 
and increase it by 5 μg/kg per minute every 3 minutes up 
to a maximum dobutamine dose of 20 μg/kg per minute. 
We recommend discontinuation of β-blockers ≥ 24 hour 
before the test, because they may attenuate the response 
of the myocardium to inotropic stimulation. At each dose 
of dobutamine, we acquire echocardiographic data for 
measurement of peak aortic velocity, mean trans-aortic 
gradient (MTAG), aortic valve area (AVA), stroke volume 
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(SV) and left ventricular ejection fraction (LVEF). Performing 
DSE is mandatory to measure flow reserve, also termed 
contractile reserve, which is defined as > 20% increase 
in SV. Flow reserve is calculated as follows: flow reserve 
(%) = (SVpeak – SVrest)/SVrest × 100 where SV = 0.785 × LVOT 
(left ventricular outflow tract) diameter2 × LVOT TVI (time 
velocity integral), respectively, at rest and at peak stress. 
The endpoints for terminating infusion of dobutamine 
are: (1) HR > 220 – age; (2) systolic BP < 80 mm Hg or 
> 220 mm Hg; (3) ischaemia detected using ECG (> 5 mm 
flat or down-sloping ST depression); (4) complex ventricular 
arrhythmias or rapid new atrial arrhythmias; (5) breathless-
ness, angina, dizziness, or syncope; and (6) maximum dose 
reached (20 μg/kg per minute) [9].
Exercise testing in the setting of VHD has previously 
been demonstrated to be safe [7, 10], especially when 
a bicycle in semi-supine or supine position is used because 
of a lower risk of haemodynamic collapse in this position 
compared with treadmill test.
Indications
Asymptomatic severe AS [asymptomatic  
severe high-flow, high-gradient (HFHG) AS
The onset of symptoms in severe HFHG AS (peak aortic 
velocity ≥ 4 m/s, MTAG ≥ 40 mm Hg, and AVA ≤ 1.0 cm2 or 
AVA index ≤ 0.60 cm2/m2) is the main indication for aortic 
valve replacement (AVR) and the main contraindication for 
exercise testing [11]. However, about one third of patients 
who deny symptoms, develop symptoms on exertion, and 
this can be unmasked by performing exercise ECG [12]. 
Patients with symptoms provoked by exercise testing 
should be considered symptomatic, even if their clinical 
history is equivocal. An exercise test is considered normal 
if the patient remains asymptomatic (no angina, limiting 
dyspnoea at low workload (i.e., during the first steps of 
exercise), syncope (or near-syncope) during the test with an 
adequate increase in systolic BP (> 20 mm Hg) and absence 
of complex ventricular arrhythmias. A positive exercise test 
(i.e. hypotension or failure to increase BP > 20 mm Hg, 
symptoms and ST-segment abnormalities) in patients with 
severe AS has prognostic significance — predicts the rapid 
occurrence of symptoms and cardiac death [11, 13]. It is 
important to know, that during exercise in > 80% of patients 
with AS, horizontal or down-sloping ST-depression > 2 mm 
is seen and those ST segment changes are nonspecific for 
diagnosis of CHD.
EE has an additive prognostic value over clinical 
findings, echocardiography at rest, and exercise ECG. 
While performing EE, an increase in MTAG by ≥ 18– 
–20 mm Hg shows the increased risk of cardiac events 
and reflects more severe AS with a noncompliant, rigid 
aortic valve [14–16]. Changes in LV function during 
exercise also carry important prognostic information. 
Limited contractile reserve (i.e., a decrease or a limited 
increase in LVEF) is associated with faster development 
of symptoms and increased risk of cardiovascular death 
[17, 18]. Standard LVEF measurements are insensitive 
to detect subclinical LV systolic dysfunction, therefore 
more sophisticated technique, such as assessment of 
longitudinal LV function (i.e. analysing global longitudinal 
strain (GLS) by using 2-dimensional speckle tracking) 
seems to be a more powerful predictor of the occurren-
ce of symptoms, exercise intolerance, and outcomes 
in AS [19, 20]. Other haemodynamically important 
parameters, such as increase of LV filling pressure or 
systolic pulmonary artery pressure (SPAP) with exercise, 
might predict the occurrence of symptoms in HFHG AS 
patients (Figure 1) [21, 22]. We still need prospective 
clinical trials evaluating the role of exercise-induced 
echocardiographic changes, such as increase in MTAG, 
limited LV contractile reserve or exercise-induced pulmo-
nary hypertension as clear indications of AVR in severe 
asymptomatic HFHG AS.
As reported in several prospective and retrospective 
studies, the exercise testing is safe in asymptomatic pa-
tients with AS [23]. Exercise testing is recommended in 
physically active patients for unmasking symptoms and 
for risk stratification of asymptomatic patients with severe 
aortic stenosis [2].
Clinical practice implications (Table 1):
 — current ESC/EACTS and AHA/ACC guidelines agree, that 
exercise testing is useful in patients with asymptomatic 
severe AS. Guidelines recommend/consider surgical 
AVR in asymptomatic severe AS and symptoms on 
exercise testing clearly related to AS (ESC/EACTS IC; 
ACC/AHA IIaB) or fall in BP at exercise below baseline 
(ESC/EACTS IIaC; ACC/AHA IIaB) [2, 3];
 — regarding exercise stress echocardiography, ESC/ 
/EACTS guidelines says, that it may provide prognostic 
information in asymptomatic severe AS by assessing 
the increase in MTAG and change in LV function during 
exercise [2];
 — exercise testing should not be performed in symptoma-
tic patients with AS, when the aortic velocity is 4.0 m 
per second or greater or mean pressure gradient is 
40 mm Hg or higher (ACC/AHA IIIB) [3].
Low-flow, low-gradient aortic stenosis  
(LFLG AS) with reduced LV ejection fraction
LFLG AS with LV dysfunction refers to the patients with 
severe AS (AVA < 1.0 cm2; ≤ 1.0 cm2 in ACC/AHA guide-
lines), low MTAG (< 40 mm Hg), impaired LVEF (< 40%; 
< 50% in ACC/AHA guidelines) and low-flow condition (SV 
index < 35 mL/m2) [2, 3, 9]. However, when the MTAG 
is < 40 mm Hg, a small AVA does not definitely confirm 
severe AS and two different situations can be observed: 
1) true severe AS with reduced LVEF caused by excessive 
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afterload and concomitant myocardial dysfunction; 
2) pseudo-severe AS caused by primary myocardial dys-
function with only moderate AS and reduced aortic leaflet 
opening due to a low trans-aortic volume flow rate. DSE 
is helpful in this setting by distinguishing truly severe AS 
from pseudo-severe AS (Figure 2). The main objective of 
DSE is to increase the trans-valvular flow rate using the 
above-mentioned dobutamine protocol (up to 20 μg/kg 
per minute) to achieve a steady state and avoid tachy-
arrhythmia or ischaemia [9]. Truly severe AS is defined as 
an increase in MTAG to > 40 mm Hg, a minimal changes 
in AVA (< 0.3 cm2) and/or AVA during dobutamine stress 
≤ 1.0–1.2 cm2, and particularly the presence of flow 
reserve (i.e., > 20% increase in SV) during low dose DSE 
[2]. Pseudo-severe AS is characterised by a significant 
increase in AVA (≥ 0.3 cm2) and/or an AVA with dobutamine 
stress > 1.2 cm2, and an MTAG remaining < 40 mm Hg, 
explained by greater opening of the aortic valve leaflets 
with increasing volume flow rate during pharmacological 
stress. Low-dose DSE by differentiating between true 
severe and pseudo-severe AS, helps to identify patients, 
that will significantly benefit from AVR, i.e. patients with 
true severe AS and impaired LV function. Patients with 
pseudo-severe AS, in contrary, do not benefit from AVR 
and may also have a higher perioperative mortality [9]. 
The latter patients should be treated with aggressive heart 
failure therapy and they might require AVR if medical the-
rapy fails to improve their condition and/or if the stenosis 
progresses to the severe stage [24].
In addition to the above-described patient groups, 
low-dose DSE helps to identify a third group of patients 
who fail to show an increase in SV > 20% with dobuta-
mine, referred to as “lack of flow or contractile reserve” 
(Figure 3). This subgroup of patients appears to have 
a very poor prognosis [3]. Despite high surgical mortality, 
5-year mortality is significantly lower after AVR (31%) com-
pared with medical therapy alone (87%) in this patients 
group [25]. In such patients, AS severity often remains 
indeterminate after DSE and another imaging modality, 
such as aortic calcification quantification using multislice 
computed tomography (CT), might be useful to assess 
stenosis severity and indications for surgery (Figure 2). 
Figure 1A–D. Doppler findings at rest (left panels) and at exercise (right panels) obtained while performing EE in asymptomatic patient 
with severe AS. Although increase in MTAG was ~10 mm Hg (nonsignificant) (A and B), exercise-induced dyspnoea, decrease in LVEF (from 
55 to 45%) and SV by 12 mL (C and D) and increase in trans-tricuspid gradient (from 45 to 79 mm Hg) were observed, all of which represent 
haemodynamically significant symptomatic AS. The patient underwent surgical AVR-; AV — aortic valve; AVA — aortic valve area; AV Env; 
Ti — aortic time interval; HR — heart rate; LVCO — left ventricular cardiac output; LVOT — left ventricular outflow tract; LVSV — left ventricular 
stroke volume; maxPG — maximal pressure gradient; meanPG — mean pressure gradient; MTAG — mean trans-aortic gradient; SV — stroke 
volume; SVI — stroke volume index; Vmax — maximal velocity; Vmean — mean velocity; VTI — velocity time integral
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Table 1. Summary of indications for exercise ECG and stress imaging in VHD 
VHD Stress  
protocol
Parameters  
to monitor*
Criteria indicating signi-
ficant lesion
ESC/EACTS and ACC/AHA guidelines 
Exercise ECG Stress imaging
Asymptomatic 
HFHG AS
Exercise 
ECG or EE
Symptoms, BP 
response, MTAG 
(LVEF, SPAP, GLS, 
E/Ea**)
Development of symp-
toms, fall in BP below 
baseline, increase in 
MTAG > 20 mm Hg
Decision to perform 
AVR: ESC/EACTS — IC 
(symptoms) or IIaC (fall 
in BP), ACC/AHA — IIaB 
(symptoms or fall in BP)
EE may provide progno-
stic information (increase 
in MTAG and change in 
LVEF) (ESC/EACTS)
Symptomatic 
LFLG AS 
Low dose 
DSE only
Vmax, MTAG, SV, 
AVA (LVEF, AVAproj)
SV > 20%,  
Vmax ≥ 4.0 m/s,  
MTAG ≥ 40 mm Hg, 
increase in  
AVA < 0.3 cm2,  
AVA ≤ 1.0–1.2 cm2
No recommendations Decision to perform AVR: 
ESC/EACTS IC (with flow 
reserve), IIaC (without 
flow reserve); ACC/AHA — 
IIaB (with flow reserve)
Asymptomatic 
severe AR
Exercise 
ECG
Symptoms, fun-
ctional capacity
Development of symp-
toms, decreased fun-
ctional capacity
Can be used (ACC/
AHA)/should be perfor-
med (ESC/EACTS) for 
objective assessment 
of exercise capacity and 
symptom status
No recommendations
Asymptomatic 
at least mo-
derate MS or 
symptomatic 
mild MS
Stress 
(preferably 
exercise) 
echocardio-
graphy
Symptoms, fun-
ctional capacity, 
MTMG, SPAP 
SPAP > 60 mm Hg, 
MTMG > 15 mm Hg, 
symptoms, decreased 
functional capacity 
Indicated in asympto-
matic patients or pa-
tients having equivocal 
or discordant symptoms 
with the severity of MS 
(ESC/EACTS)
EE recommended: ACC/
AHA IC (may provide addi-
tional objective informa-
tion ESC/EACTS) 
Decision to perform 
PMC: ACC/AHA IIbC 
(MTMG > 15 mm Hg)
Asymptomatic 
severe/sympto-
matic moderate 
primary MR
Exercise 
ECG, EE, 
cardio-
-pulmonary 
exercise 
testing
Symptoms, fun-
ctional capacity, 
SPAP 
(EROA, LV contra-
ctile reserve)
Development of symp-
toms, decreased fun-
ctional capacity, SPAP 
≥ 60 mm Hg
Should be considered: 
ACC/AHA IIaC
EE should be considered: 
ACC/AHA IIaB 
Decision to perform MV 
repair: no recommenda-
tions in both guidelines
Severe/mode-
rate secondary 
MR
DSE, EE, 
SPECT, PET, 
CMR
Symptoms,  
inotropic reserve 
(viability),  
(SPAP, EROA)
Viability, increase in 
EROA ≥ 13 mm2
No recommendations ESC/EACTS guidelines 
recommend to consider 
EE in moderate MR 
For viability assessment: 
ECC/AHA IC, ESC/EACTS 
may be useful 
Decision to perform MV 
correction during CABG: 
severe MR (ESC/EACTS 
IC, ACC/AHA IIaC), mo-
derate MR (ESC/EACTS 
likely to be considered 
in the presence of viabi-
lity and low comorbidity, 
ACC/AHA IIbB-R)
*In italics there are indicated parameters not mentioned in the both guidelines and more clinical trial data are needed for use them routinely 
in clinical practice; **measured before E and A wave fusion; AVA — aortic valve area; BP — blood pressure; DSE — dobutamine stress echo-
cardiography; E — diastolic mitral inflow velocity; Ea — early diastolic annulus velocity; ECG — electrocardiogram; EROA — effective regurgitant 
orifice area; EE — exercise echocardiography; GLS — global longitudinal strain; LV — left ventricular; LVEF — left ventricular ejection fraction; 
MTAG — mean trans-aortic gradient; MTMG — mean trans-mitral gradient; MVR — mitral valve replacement; PHT — pulmonary hypertension; 
PMC — percutaneous mitral commissurotomy; RVol — regurgitant volume; SPAP — systolic pulmonary artery pressure; SV — stroke volume; 
TAPSE — tricuspid annular plane systolic excursion
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Instead of one suggested cut-off value for calcium score in 
Figure 2, ESC/EACTS guidelines recommend to use more 
precise assessment of likelihood of severe AS: severe AS 
very likely if Agatston calcium score is ≥ 3000 in men and 
≥ 1600 in women; severe AS is likely if Agatston calcium 
score is ≥ 2000 in men and ≥ 1200 in women and severe 
AS is likely if Agatston calcium score is < 1600 in men 
and < 800 in women [2].
Some patients may have an equivocal response to 
DSE (i.e., a peak trans-aortic gradient of 30 mm Hg and 
an AVA of 0.8 cm2) due to variable increases in flow. In 
those cases, interpretation of the DSE results is difficult 
without considering the relative changes in flow. To solve 
the above-mentioned problem, the researchers of the TO-
PAS (truly or pseudo-severe aortic stenosis) trial proposed 
to calculate the projected AVA that would have occurred at 
a standardised flow rate of 250 mL/s (AVAproj). Projected AVA 
has been shown to be more closely related to actual AS 
severity, myocardial blood flow impairment, flow reserve, 
and survival than the traditional DSE parameters [26, 27]. 
The AVAproj is calculated as follows: 
AVAproj = (AVApeak – AVArest)/(Qpeak – Qrest) × (250 – Qrest) + 
AVArest, where AVArest and Qrest, and AVApeak and Qpeak are AVA 
calculated by continuity equation and Q by dividing SV (mL) 
by LV ejection time (s) at rest and at peak DSE, respectively 
[11]. An AVAproj ≤ 1.0 cm2 is considered to be severe, but the 
full role of the AVAproj still needs evaluation by randomised 
clinical studies in the future.
Clinical practice implications (Table 1):
 — in symptomatic severe LFLG (< 40 mm Hg) AS and redu-
ced LVEF, AVR is recommended/should be considered 
after the demonstration of truly severe AS with evidence 
of flow (contractile) reserve using low dose DSE (ESC/ 
/EACTS IC; ACC/AHA IIaB) [2, 3];
 — in symptomatic LFLG AS and reduced LVEF without flow 
(contractile) reserve during low dose DSE, AVR should 
be considered, particularly when CT calcium scoring 
confirms severe AS (ESC/EACTS IIaC) [2].
Severe asymptomatic aortic regurgitation (AR)
Symptomatic patients with severe AR have a markedly 
increased mortality rate [29], and they benefit from AVR 
Figure 2. Clinical decision-making algorithm in severe LFLG AS with reduced LVEF. Parameters between parentheses represent new indi-
ces requiring further validation; AVA — aortic valve area;, AVAproj. — projected AVA at normal flow rate; MTAG — mean trans-aortic gradient; 
Ca — calcium score (Agatston unit) (see text for more profound explanation); SV — stroke volume; SAVR — surgical aortic valve replacement, 
TAVR — trans-catheter aortic valve replacement; *cut-off points could be slightly different depending on a study; **see text for explanation. 
Adapted with permission from [28]
LVEF ≤ 40%
MTAG < 40 mm Hg
AVA ≤ 1.0
DSE
LV ﬂow reserve
Przeciążenie RV
SV  20% SV < 20%
No LV ﬂow reserve
MTAG > 40* 
and AVA < 1.2*
(AVAproj ≤ 1.0–1,2)
(CT Ca  1650)
MTAG  40* 
and AVA < 1.2*
(AVAproj ≤ 1.0–1,2)
(CT Ca  1650)
(AVAproj < 1.0–1,2)**
(CT Ca  1650)
No Yes
True-severe AS Pseudo-severe AS True-severe AS
SAVR ± CABG MEDICAL TREATMENT SAVR (high surgical risk)
TAVR?
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[2, 3]. According to ACC/AHA guidelines, exercise testing 
can be used to prove the presence of symptoms and to 
assess functional capacity in patients with AR [3]. The use 
of EE on routine basis in patients with severe asymptomatic 
AR is not recommended. If the decision to perform EE is 
taken, the main goal of EE should be to unmask the symp-
toms and subclinical LV dysfunction using standard LVEF 
measurement or LV longitudinal function assessment [9]. 
In our laboratory, we perform EE in selected AR patients, 
mostly when there are discrepancies between resting 
echocardiographic data and symptoms.
Clinical practice implications — see Table 1.
 — As the additional value of exercise testing or EE is 
still not clear, both guidelines highlight, that the key 
examination procedure in AR still remains rest echo-
cardiography [2, 3]. ESC/EACTS guidelines says, that 
in patients not reaching the thresholds for surgery, 
close follow-up is needed and exercise testing sho-
uld be performed to identify borderline symptomatic 
patients [2].
Mitral stenosis (MS)
Echocardiography is the main method for the assessment 
of the MS severity and consequences. Discrepancies be-
tween symptom status and severity of MS are frequent. 
Therefore, an exercise test, and particularly EE should be 
considered for objective assessment of functional capacity 
and unmasking symptoms in patients, who deny symptoms 
or have doubtful symptoms. Semi-supine EE is now pre-
ferred technique, as it allows assessing the trans-mitral 
gradient and SPAP at each step of increasing workload. 
Haemodynamic changes at effort are highly variable for 
a given degree of stenosis. Although DSE has been shown 
to have prognostic value in patients with MS [30], but in 
Figure 3A–D. Doppler findings obtained while performing DSE in symptomatic male patient with LFLG AS. At rest (left panels) there is 
low-flow situation with SVI of about 35 mL/m2 (C) and low gradient with an MTAG of 26 mm Hg (A). At peak low dose DSE (left panels) the 
absence of LV flow reserve (15% increase in SV) (D) and indeterminate severity of AS (MTAG = 30 mm Hg, AVA – 1.1 cm2) (B) was observed. 
After the assessment of calcium score by CT (1000 Agatston units) it was decided to treat patient conservatively. Abbreviations are the 
same as in Figure 1
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general is a less physiological approach than EE and in our 
centre is not used for this purpose.
By performing EE, it is possible to assess patient’s 
functional capacity, exercise-induced symptoms, mean 
trans-mitral gradient (MTMG) and SPAP during exercise (Fi-
gure 4). The dynamic assessment, according to the recent 
study, is essential to define the real severity of MS [31]. In 
the earlier ACC/AHA guidelines, an increase in MTMG to 
≥ 15 mm Hg or SPAP to ≥ 60 mm Hg was considered a class 
IIb indication for percutaneous mitral balloon commissuro-
tomy (PMC) [32]. However, cut-off values for interpreting the 
results of the test in MS remain arbitrary, based on expert 
consensus agreement and not supported by outcome data 
from large randomised clinical trials [11, 33, 34]. Therefore, 
further clinical research evaluating the impact of exercise 
Doppler data on outcome is still needed.
Clinical practice implications (Table 1):
 — EE is recommended in ACC/AHA guidelines in patients, 
who present a discrepancy between resting Doppler 
echocardiographic findings and clinical symptoms or 
signs (ACC/AHA IC) [3]. According to ESC/EACTS gu-
idelines, stress testing is indicated in patients with no 
symptoms or symptoms equivocal or discordant with 
the severity of MS. EE may provide additional objective 
information by assessing changes in MTMG and SPAP 
[2]. Truly asymptomatic patients, as assessed using 
stress testing, are usually not candidates for the PMC, 
except in cases, where there is increased risk of syste-
mic embolism or haemodynamic decompensation [2];
 — PMC may be considered in symptomatic patients with 
mitral valve area > 1.5 cm2 if there is evidence of 
haemodynamically significant MS based on increase 
in MTMG to > 15 mm Hg during exercise (ACC/AHA 
IIbC) [3].
Figure 4A–D. Doppler findings obtained by performing EE in an asymptomatic patient with moderate rheumatic MS (MVA 1.3 cm2) at rest 
(left panels). The increase in MTMG during exercise was significant (MTMG increased up to 19 mm Hg) (A and B) with a significant increase 
in TTG up to 73 mm Hg (C and D) and exercise-induced dyspnoea. The patient underwent PMC; HR — heart rate; maxPG — maximal pressure 
gradient; meanPG — mean pressure gradient; MTMG — mean trans-mitral gradient; MV — mitral valve; MVA — mitral valve area; TTG — trans-
-tricuspid gradient; Vmax — maximal velocity; Vmean — mean velocity; VTI — velocity time integral
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Mitral regurgitation (MR)
The importance of SE for evaluating patients with regurgi-
tant VHD is becoming more significant and its clinical value 
has been extensively demonstrated in patients with MR[8]. 
Assessing the patients with chronic MR, there is a need 
to divide this VHD according to the mechanism of MR into 
two groups: primary and secondary MR [3].
Degenerative (primary) MR
Primary MR covers all aetiologies, in which intrinsic lesions 
affect one or several components of the mitral valve appa-
ratus [2]. It is a primary disease of the valve, but not left 
ventricle. In general, surgery is recommended in patients 
who have symptoms due to chronic primary MR, but no 
contraindications to surgery.
The main method to assess the severity of asympto-
matic primary MR is resting echocardiography. In general, 
the effective regurgitant orifice area (EROA) ≥ 40 mm2 and 
regurgitant volume (RVol) ≥ 60 mL defines severe prima-
ry MR. However, primary MR is a dynamic process and 
exercise testing might identify patients with unrecognised 
symptoms or clarify symptoms that are out of proportion 
with resting MR severity [9]. For more than one third of 
the patients with primary MR, moderate MR may deve-
lop during exercise into severe MR [8]. In such cases, 
EE is used to evaluate exercise capacity, subclinical LV 
dysfunction, unrecognised symptoms, and to determine 
patients that may benefit from early surgery [1]. Patients 
with worsening of MR severity, a marked increase in SPAP 
(> 60 mm Hg), decreased exercise capacity and the oc-
currence of symptoms during EE are those patients, that 
likely will benefit from early surgery [11]. In chronic asymp-
tomatic moderate to severe primary MR, a marked increase 
in MR severity (increase of EROA ≥ 10 mm2 and RVol 
≥ 15 mL) with exercise well correlated with exercise-indu-
ced pulmonary hypertension [34]. The main detrimental 
consequence of dynamic MR is the occurrence of pulmo-
nary hypertension during exercise, which is associated with 
a markedly reduced two-year symptom-free survival and 
is a more accurate predictor of progression to symptoms 
compared with resting SPAP [9]. EE is useful to unmask 
subclinical LV dysfunction associated with MR, especially 
in cases with borderline LVEF (60–65%) or LV end-systolic 
diameter (near 40 mm or 22 mm/m2) [35]. Absence of 
contractile reserve (i.e. the inability to increase LVEF by 
> 4% with exercise) has been associated with LV dysfun-
ction after mitral valve surgery, and progressive decrease 
in LV function without surgery [36]. Moreover, the absence 
of LV contractile reserve measured using LV GLS (increase 
< 2% with exercise) has been associated with the higher 
risk of cardiac complications [37].
For the management of patients with chronic prima-
ry MR, three different exercise tests can be used — EE, 
exercise ECG and cardiopulmonary exercise testing. EE in 
a semi-supine position should be used to evaluate chronic 
primary MR. Importantly, the assessment of haemodynamic 
component (especially EROA) of primary MR during exercise 
particularly requires experience and the learning curve of 
the EE performing physician should be taken into account. 
DSE is not useful because of the haemodynamic effects 
leading to decreases of preload and afterload. Additional 
information about a cardiac or non-cardiac limitation can be 
obtained while performing cardiopulmonary exercise test.
According to ACC/AHA guidelines [3], EE should be 
considered in symptomatic patients with chronic primary 
MR in case there is a disagreement between the symptoms 
and the severity of MR at rest (IIaB). In the latter cases, the 
increase in severity of MR and/or SPAP helps to explain 
exercise-induced symptoms and indicates the early mitral 
surgery (Figure 5). Additionally, exercise testing can be 
useful for unmasking the symptom status and for evalua-
tion of exercise tolerance (IIaC) [3]. ESC/EACTS guidelines 
[2] express similar opinion by stating, that EE is useful to 
quantify changes in MR, SPAP and LV function during exer-
cise, especially in patients with symptoms and uncertainty 
about the severity of MR based on measurements at rest. 
Additionally, determination of functional capacity while 
performing cardiopulmonary exercise testing, may give 
useful information regarding symptoms status [38]. Mo-
reover, new parameters, such as exercise-induced changes 
in LV volumes, LVEF and GLS may predict LV dysfunction 
after valve surgery [39]. The use of GLS is still limited by 
inconsistent algorithms used by different commercially 
available echocardiographic systems [2].
Clinical practice implications (Table 1):
 — EE should be considered in symptomatic patients with 
chronic primary MR in case there is a discrepancy be-
tween symptoms and the severity of MR at rest (ACC/ 
/AHA IIaB) [3];
 — However, haemodynamic criteria provided by EE that 
may indicate surgery have not been sufficiently well 
defined to be included in the current recommendations 
[2, 3].
Ischaemic (secondary) MR
Secondary MR is not the primary disease of the valve as 
primary MR, but it is caused by the geometrical distor-
tion of the subvalvular apparatus, secondary due to LV 
enlargement and remodelling due to idiopathic dilative 
cardiomyopathy or CHD [2].
The indications for isolated mitral valve surgery in 
symptomatic patients with severe secondary MR (EROA 
≥ 20 mm2 and RVol ≥ 30 mL) and severe systolic LV dysfun-
ction with no option for revascularisation are questionable. 
Repair may be considered in selected patients with low 
comorbidity, in order to avoid or postpone heart transplan-
tation. In the other patients, the optimal contemporary 
heart failure treatment (including heart resynchronisation 
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therapy) is currently the best option [2]. There is a conti-
nuing debate regarding the need for surgical correction 
of moderate ischaemic MR in patients undergoing coro-
nary artery bypass grafting (CABG). Mitral valve surgery is 
more likely to be considered in patients with low LVEF, if 
substantial amount of viable myocardium is present and 
if comorbidity is low.
As ischaemic MR is a highly dynamic condition and 
can manifest clinically as intermittent pulmonary oedema 
or dyspnoea. Therefore, according to ESC/EACTS guide-
lines, EE may provide prognostic information of dynamic 
characteristics of secondary MR [2]. An increase of EROA 
≥ 13 mm2 during exercise is associated with a significant 
increase in the relative risk of death and hospitalisation due 
to heart failure [40]. The prognostic value of dynamic MR 
has not been validated in non-ischaemic cardiomyopathy. 
EE remains the best modality to evaluate the dynamic 
component of secondary MR, because DSE leads to con-
founding effects caused by reduction in loading conditions 
[9]. EE can provide useful information in patients with LV 
dysfunction and: 1) exertional dyspnoea, which is out of 
proportion to the MR severity or LV dysfunction at rest; 2) 
acute pulmonary oedema without a clear cause; 3) mode-
rate MR before surgical revascularisation [41]. EE is useful 
for risk stratification of mortality and heart failure [42]. 
Cut-off values of significant exercise-induced increase in 
MR should undergo validation in a large prospective rando-
mised trial. Importantly, the assessment of haemodynamic 
component of secondary MR during EE particularly requires 
experience, and the learning curve of the EE performing 
physician should be taken into account. Exercise-induced 
dyspnoea, marked increase in MR severity and exercise-
-induced pulmonary hypertension favour combined surgery 
— CABG together with surgical MV correction (preferably 
repair). The prognostic value of exercise test for predicting 
the results of surgical treatment still requires evaluation.
Additionally, in patients with ischaemic MR, DSE may 
be used to assess the viable myocardium and predict the 
Figure 5A–D. Doppler findings in a symptomatic patient with moderate primary MR and borderline SPAP at rest (upper panels). During EE, 
a marked increase in MR associated with pulmonary hypertension (lower panels) and exercise-induced symptoms was observed. The patient 
underwent MV repair; EROA — effective regurgitant orifice area; TTG — trans-tricuspid gradient
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response to revascularisation [1]. ACC/AHA guidelines [3] 
recommend to perform non-invasive imaging (nuclear mo-
dalities, cardiovascular magnetic resonance (CMR), or SE), 
cardiac CT angiography, or cardiac catheterisation, including 
coronary arteriography, for establishing the aetiology of 
chronic secondary MR and/or to assess viable myocardium 
(IC). ESC/EACTS guidelines says, that the myocardial viability 
testing may be useful in patients with ischaemic secondary 
MR, who are candidates for revascularisation [2]. There is 
no clear place for quantitative assessment of secondary 
MR using EE in the ACC/AHA guidelines.
Clinical practice implications (Table 1):
 — in patients with moderate to severe secondary MR and 
LV dysfunction, CHD and myocardial viability should be 
assessed (ACC/AHA IC) [3];
 — severe secondary MR according to ESC/EACTS (IC, in 
case LVEF >30%) and ACC/AHA (IIaC) guidelines, should 
be addressed during CABG [2, 3];
 — management of patients having moderate MR is contro-
versial. ESC/EACTS guidelines recommend considering 
EE in patients capable of exercising to assess exercise-
-induced dyspnoea, increase in MR severity and SPAP 
during exercise [2]. According to ESC/EACTS guidelines, 
combined surgery is more likely to be considered if 
myocardial viability is present and if comorbidity is low 
[2]. According to recent ACC/AHA guidelines update in 
patients with chronic, moderate, ischaemic MR under-
going CABG, the usefulness of mitral valve repair is 
uncertain (IIbB-R) [42].
Conclusions
Although the surgical treatment of VHD continue to be ba-
sed on symptoms and resting LV morphology and function, 
the growing evidence have confirmed the additive progno-
stic value of the assessment of exercise-induced symptoms 
and exercise capacity, and evaluation of the haemodynamic 
components of VHD using SE, particularly EE. SE can be 
useful for risk stratification and timing of surgery in VHD. 
The incremental prognostic value of EE has been shown 
in the setting of AS and MR. DSE has its strong in patients 
with LFLG AS for assessing aortic stenosis severity and for 
operative risk stratification. Further randomised clinical 
trials are required to confirm the impact of clinical decisions 
making based on stress imaging data on outcome in VHD 
patients. More data are still needed regarding the value of 
new parameters obtained by 3D EE, tissue Doppler EE and 
exercise strain imaging. Despite the lacking evidence, EE is 
useful modality in selected VHD patients and experienced 
hands, and its broader use is warranted.
Streszczenie
Autorzy analizują znaczenie elektrokardiografii wysiłkowej i elektrokardiografii obciążeniowej u osób z chorobą za-
stawkową serca (valvular heart diseases, VHD) na podstawie najnowszych danych naukowych oraz zaleceń zawartych 
w wytycznych European Society of Cardiology/European Association of Cardio-Thoracic Surgery (ESC/EACTS) i Ameri-
can College of Cardiology/American Heart Association (ACC/AHA) dotyczących diagnozowania i leczenia VHD. W obu 
wytycznych podkreśla się rolę elektrografii wysiłkowej w ujawnianiu w obiektywnym badaniu występowania objawów 
u chorych, którzy żadnych objawów nie zgłaszają lub mają objawy budzące wątpliwości, jednak kwestionuje się znacze-
nie echokardiografii obciążeniowej w ocenie hemodynamicznej komponenty VHD i wykrywaniu bezobjawowej dysfunkcji 
miokardium. Powyższe wytyczne zdecydowanie zalecają, aby podejmować decyzję dotyczące chirurgicznego leczenia 
choroby zastawkowej na podstawie występowania objawów oraz parametrów morfologicznych i funkcjonalnych lewej 
komory ocenianych w spoczynku. Echokardiografia obciążeniowa może być przydatna u wybranych chorych z VHD do 
ustalenia rokowania, wyjaśniania przyczyny objawów i podejmowania decyzji dotyczących terminu zabiegu chirurgicz-
nego. Mimo że istnieją dane naukowe na temat obrazowania obciążeniowego, potrzebne są randomizowane badania 
kliniczne oceniające ich znaczenie w podejmowaniu decyzji w codziennej praktyce klinicznej.
Słowa kluczowe; elektrokardiografia wysiłkowa, elektrokardiografia obciążeniowa, próba dobutaminowa, obrazowanie 
obciążeniowe, choroba zastawkowa serca
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